dc.contributor.author
Dorn, Christoph
dc.contributor.author
Petroff, David
dc.contributor.author
Kratzer, Alexander
dc.contributor.author
Kees, Frieder
dc.contributor.author
Kloft, Charlotte
dc.contributor.author
Zeitlinger, Markus
dc.contributor.author
Wrigge, Hermann
dc.contributor.author
Simon, Philipp
dc.date.accessioned
2022-09-20T09:14:55Z
dc.date.available
2022-09-20T09:14:55Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/36384
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-36100
dc.description.abstract
Background and Objective
Tigecycline, a broad-spectrum glycylcycline antibiotic, is approved for use at a fixed dose irrespective of body weight. However, its pharmacokinetics may be altered in obesity, which would impact on the antibiotic’s effectiveness. The objective of this study was to investigate the plasma and subcutaneous tissue concentrations of tigecycline in obese patients compared with those in a non-obese control group.
Methods
Fifteen obese patients (one class II and 14 class III) undergoing bariatric surgery and 15 non-obese patients undergoing intra-abdominal surgery (mainly tumour resection) received a single dose of 50 or 100 mg tigecycline as an intravenous short infusion. Tigecycline concentrations were measured up to 8 h after dosing in plasma (total concentration), in ultrafiltrate of plasma (free concentration), and in microdialysate from subcutaneous tissue, respectively.
Results
In obese patients, total peak plasma concentration (1.31 ± 0.50 vs 2.27 ± 1.40 mg/L) and the area under the concentration–time curve from 0 to 8 h (AUC8h,plasma: 2.15 ± 0.42 vs 2.74 ± 0.73 h⋅mg/L), as normalized to a 100 mg dose, were significantly lower compared with those of non-obese patients. No significant differences were observed regarding the free plasma concentration, as determined by ultrafiltration, or the corresponding AUC8h (fAUC8h,plasma). Concentrations in interstitial fluid (ISF) of subcutaneous tissue were lower than the free plasma concentrations in both groups, and they were lower in obese compared to non-obese patients: the AUC8h in ISF (AUC8h,ISF) was 0.51 ± 0.22 h⋅mg/L in obese and 0.79 ± 0.23 h⋅mg/L in non-obese patients, resulting in a relative tissue drug exposure (AUC8h,ISF/fAUC8h,plasma) of 0.38 ± 0.19 and 0.63 ± 0.24, respectively.
Conclusion
Following a single dose of tigecycline, concentrations in the ISF of subcutaneous adipose tissue are decreased in heavily obese subjects, calling for an increased loading dose.
en
dc.format.extent
7 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
pharmacokinetics
en
dc.subject
antibiotic’s effectiveness
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.title
Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s13318-022-00789-2
dcterms.bibliographicCitation.journaltitle
European Journal of Drug Metabolism and Pharmacokinetics
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.pagestart
749
dcterms.bibliographicCitation.pageend
755
dcterms.bibliographicCitation.volume
47
dcterms.bibliographicCitation.url
https://doi.org/10.1007/s13318-022-00789-2
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
2107-0180
refubium.resourceType.provider
WoS-Alert